相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Licochalcone A Inhibits Cellular Motility by Suppressing E-cadherin and MAPK Signaling in Breast Cancer
Wen-Chung Huang et al.
CELLS (2019)
A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence
Marcia Fournier et al.
SCIENTIFIC REPORTS (2019)
Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins
Carrie J. Lovitt et al.
BMC CANCER (2018)
Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system
Hani M. Babiker et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Update on the Treatment of Early-Stage Triple-Negative Breast Cancer
Priyanka Sharma
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Molecular mechanism of doxorubicin-induced cardiomyopathy - An update
Kaviyarasi Renu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
Touko Inao et al.
Oncotarget (2018)
Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells
Sony Pandey et al.
Oncotarget (2018)
Targeting BCL-2 regulated apoptosis in cancer
Kirsteen J. Campbell et al.
OPEN BIOLOGY (2018)
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
Claudia Omarini et al.
CANCER MANAGEMENT AND RESEARCH (2018)
ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line
Eunjoo Hwang et al.
ANNALS OF SURGICAL TREATMENT AND RESEARCH (2018)
Triple-negative breast cancer and the potential for targeted therapy
Jing-Ru Jhan et al.
PHARMACOGENOMICS (2017)
Establishment and characterization of a triple negative basal-like breast cancer cell line with multi-drug resistance
Sergei Boichuk et al.
ONCOLOGY LETTERS (2017)
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation
Kyung-Min Lee et al.
CELL METABOLISM (2017)
Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells
Li-han Zhang et al.
APOPTOSIS (2016)
Long chain n-3 polyunsaturated fatty acids increase the efficacy of docetaxel in mammary cancer cells by downregulating Akt and PKCε/δ-induced ERK pathways
Lucie Chauvin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2016)
P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors
Joanna Kopecka et al.
ONCOTARGET (2016)
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
Yun-Kai Zhang et al.
AAPS JOURNAL (2015)
Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer
C. Wang et al.
ANNALS OF ONCOLOGY (2015)
The fate of chemoresistance in triple negative breast cancer (TNBC)
Elma A. O'Reilly et al.
BBA CLINICAL (2015)
Twisting and Ironing: Doxorubicin Cardiotoxicity by Mitochondrial DNA Damage
Karin C. Nitiss et al.
CLINICAL CANCER RESEARCH (2014)
Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
Justin M. Balko et al.
CANCER DISCOVERY (2014)
N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma
Shanique K. E. Edwards et al.
BMC CANCER (2013)
Topical valrubicin application reduces skin inflammation in murine models
E. Hauge et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells
Yufeng Zuo et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2012)
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Sui Zhang et al.
NATURE MEDICINE (2012)
Inhibitory effects of wogonin on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-9
Pu Chen et al.
TOXICOLOGY (2011)
Choosing the right cell line for breast cancer research
Deborah L. Holliday et al.
BREAST CANCER RESEARCH (2011)
In vivo Dynamics and Distinct Functions of Hypoxia in Primary Tumor Growth and Organotropic Metastasis of Breast Cancer
Xin Lu et al.
CANCER RESEARCH (2010)
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Yves Pommier et al.
CHEMISTRY & BIOLOGY (2010)
Protection from Doxorubicin-Induced Cardiomyopathy Using the Modified Anthracycline N-Benzyladriamycin-14-valerate (AD 198)
Chun Cai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Cardiovascular Complications of Cancer Therapy Incidence, Pathogenesis, Diagnosis, and Management
Edward T. H. Yeh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Cardiotoxicity of antitumor drugs
Pierantonio Menna et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2008)
Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems
Brian R. J. Healey Bird et al.
CLINICAL CANCER RESEARCH (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
N-benzyladriamycin-14-valerate (AD 198):: A non-cardiotoxic anthracycline that is Cardioprotective through PKC-ε activation
Polly A. Hofmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity
Leonard Lothstein et al.
LEUKEMIA RESEARCH (2007)
Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase c-δ induces its activation and facilitates mitochondrial targeting of tBid
Yongwen He et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
N-benzyladriamycin-14-valerate (AD 198) activates protein kinase C-δ holoenzyme to trigger mitochondrial depolarization and cytochrome c release independently of permeability transition pore opening and Ca2+ influx
Leonard Lothstein et al.
ANTI-CANCER DRUGS (2006)
N-benzyladriamycin-14-valerate (AD198) induces apoptosis through protein kinase C-δ-induced phosphorylation of phospholipid scramblase 3
YW He et al.
CANCER RESEARCH (2005)
Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCδ-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation
I Vucenik et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Circumvention of nuclear factor κB-induced chemoresistance by cytoplasmic-targeted anthracyclines
JD Bilyeu et al.
MOLECULAR PHARMACOLOGY (2004)
Protein kinase Cδ is responsible for constitutive and DNA damage-induced phosphorylation of Rad9
K Yoshida et al.
EMBO JOURNAL (2003)
A role for protein kinase C δ in the differential sensitivity of MCF-7 and MDA-MB 231 human breast cancer cells to phorbol ester-induced growth arrest and p21WAF1/CIP1 induction
M Shanmugam et al.
CANCER LETTERS (2001)
Effect of cyclosporin A and its vehicle on cardiac and skeletal muscle mitochondria: relationship to efficacy of the respiratory chain
H Sanchez et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Anthracycline drug targeting: cytoplasmic versus nuclear - a fork in the road
L Lothstein et al.
DRUG RESISTANCE UPDATES (2001)
Molecular models of N-benzyladriamycin-14-valerate (AD 198) in complex with the phorbol ester-binding C1b domain of protein kinase C-δ
JB Roaten et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288)
L Lothstein et al.
BIOCHEMICAL PHARMACOLOGY (2000)
分享论文
